The combination therapy of L-T4 and ATD for Graves hyperthyroidism course and the influence of recurrence, with multicenter randomized clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002233

Enrollment

Unknown

Registered

2012-06-01

Start date

2011-11-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves hyperthyroidism

Interventions

Combination group:methimazole 20mg

Combination group:L-T4 10ug

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The age from 18 to 60 years old; 2. The patients with Clinically diagnosed Graves; 3. Thyroid moderate enlargement; 4. Thyroid drug treatment without resistance.

Exclusion criteria

Exclusion criteria: 1. Lack of strumous performance of patients with hyperthyroidism; 2. Nodular thyroid swollen with hyperthyroidism or Graves disease caused by any reason other than hyperthyroidism; 3. With thyroid disease of moderate or above; 4. Thyroid is enlargement.

Design outcomes

Primary

Measure	Time frame
TSH;TT4;FT3;TT4;	—

Countries

China

Contacts

Public ContactZhang Minjuan

502364919@qq.com+86 13913029683

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026